RxSight's New Dawn: Alcon Deal and a Pause to Reset

A Change at the Helm

When Aziz Mottiwala stepped into the CEO role at RxSight just two weeks before the second‑quarter call, he inherited a company at an inflection point. The former Tarsus Pharmaceuticals commercial chief brought not only a resume in eye care but a mandate to reassess everything. His opening remarks made plain that the status quo was no longer acceptable:

We have decided to withdraw our previously issued full-year financial guidance.

The Alcon Collaboration: Validation and Capital

The headline event was the strategic collaboration with Alcon, which Aziz described as “a major milestone for the company. It provides further external validation of the technology and its broader potential. It also provides meaningful non-dilutive capital through the $200 million in upfront and potential future milestone payments, along with the potential of significant long-term royalties.” — Aziz Mottiwala, President and Chief Executive Officer · 2026-08-05 This is a structural shift. RxSight, which had been burning cash while trying to grow its own premium lens franchise, now has a deep-pocketed partner to expand the reach of its Light Adjustable Lens (value of adjustability) into Alcon's distribution channels. The $60 million upfront that landed after quarter‑end bolsters a balance sheet that already held ~$209 million in cash and short‑term investments.

The deal also reframes the company's go‑to‑market. In Q&A, Aziz noted: “Our focus right now is how do we make this partnership really come to fruition, realize the milestones, which are very significant for us in terms of the cash value that it can add over the next few years and then the royalty.” — Aziz Mottiwala, President and Chief Executive Officer · 2026-08-05 The non‑exclusive nature leaves room for other partners, but the immediate priority is execution on this one.

A Pivot from Breadth to Depth

The second-quarter numbers were sobering: total revenue of $33.7 million, but $6.5 million of that was Alcon contribution. Ex‑collaboration, product sales fell 19% year‑over‑year, and LAL unit volume dropped 9% to 24,917. Aziz's diagnosis was blunt: “I think what we're doing is pivoting now to drive depth, right? So we've established a broad user base and pivoting to depth takes a little bit of time.” — Aziz Mottiwala, President and Chief Executive Officer · 2026-08-05 He pointed to physician feedback that no one has "capped out" on LAL usage, suggesting the ceiling is not clinical but operational.

The response is a plan to double the U.S. sales force, funded by reallocating resources rather than inflating OpEx. The goal is to help practices integrate adjustability into their workflows and increase utilization per LDD. This is a direct evolution from the prior administration's "reengagement programs" — which, under Ron Kurtz, were already trying to lift utilization. The new twist is scale and urgency.

Fundamentals: In Need of a Turnaround

The financial reality is stark. Revenue has been on a downward slide for three consecutive quarters, as captured by the tendency in the fundamentals: revenue peaked at $37M in 2025Q1 and has since fallen 14%. Gross margin remains high — 76.7% GAAP, 71.2% ex‑Alcon — but the inventory drag is real. The gross margin trend shows a robust climb from negative territory to above 70% in two years, but the current quarter's 1.3pp YoY improvement masks the drag from higher inventory costs.

The stock has been hammered. The full‑history tape shows a peak of $64.29 in May 2024 and a drawdown of 90.3%. The price-to-revenue multiple now sits at 2.0x, down from 20.7x at its peak. At a market cap of $255 million, the market is discounting a much smaller future. The Alcon deal and the cash cushion provide a floor, but the path to re‑acceleration is unproven.

Contrast: The Old Playbook Versus the New

The prior earnings calls were dominated by talk of "premium IOL market" and "clinical results." Ron Kurtz, in May 2026, said: “the feedback that we're getting both from our customers and just as importantly, from our team is very positive as we continue to roll out reengagement programs.” — Ronald Kurtz, President and Chief Executive Officer · 2026-05-09 He maintained that the LAL was winning on clinical excellence. Now, Aziz's language is more about financial guidance, collaboration with Alcon, and operational discipline. The shift from clinical evangelism to strategic management is palpable.

Mark Wilterding, the CFO, provided a nuanced view: “We said that our expectation is for growth rates to improve over the course of the year.” — Mark Wilterding, Chief Financial Officer · 2026-05-09 But that was before the guidance withdrawal. The new team is deliberately avoiding making promises it can't keep.

Why It Matters

RxSight is no longer just a story of a novel technology. It is a story of a company that has recognized its go‑to‑market model needs a rebuild. The Alcon deal validates the platform but also creates an existential question: will RxSight increasingly become a supplier to a larger partner, or will it manage to maintain its own commercial identity? Aziz's plan to double the sales force suggests the latter, but it will take time and capital.

The next few quarters will be telling. The withdrawal of guidance gives management cover to make hard choices, but investors will demand a credible plan when guidance resumes in early 2027. With $269 million in cash (post‑upfront), RxSight has runway. The question, as always, is whether it can turn that runway into a takeoff.